NanoViricides highlights need for broad-spectrum antivirals amid severe flu season
NanoViricides (NYSE-A:NNVC), a clinical-stage company developing broad-spectrum antiviral drugs, has highlighted the current influenza season as an example of the need for antivirals capable of targeting multiple respiratory viruses. The US Centers for Disease Control and Prevention (CDC) has classified the 2025 to 2026 flu season as “moderately severe,” with the Influenza A/H3N2 subclade K responsible for more than 80% of cases.
NanoViricides advances Phase 2 trials for broad-spectrum antiviral NV-378 in $17B market: analysts
NanoViricides (NYSE-A:NNVC) is gearing up to tackle multiple viral threats with Phase 2 trials for its broad-spectrum antiviral NV-378, as analysts at Alliance Global Partners kick off coverage with a Buy rating and $6 price target. The biotechnology company, which is developing innovative antiviral therapies, is advancing its lead candidate NV-378 into Phase 2 trials next year, targeting a range of viral infections including Mpox, influenza, COVID-19, and respiratory syncytial virus (RSV), according to analysts at Alliance Global Partners.
NanoViricides inks regulatory services deal to advance orphan drug strategy for antiviral NV-387
NanoViricides (NYSE-A:NNVC) said on Monday it signed a master services agreement with regulatory consulting firm Only Orphans Cote LLC to support the company's orphan drug strategy for its broad-spectrum antiviral candidate NV-387. The firm, founded by former US Food and Drug Administration official Dr Timothy Cote, will help develop and prosecute orphan drug designation applications for NV-387 at the FDA's Office of Orphan Products, NanoViricides said.
NanoViricides raises cash, moves broad-spectrum antiviral NV-387 into Phase II trials
NanoViricides (NYSE-A:NNVC) is advancing its broad-spectrum antiviral NV-387, backed by new financing that strengthens its balance sheet and supports regulatory progress toward Phase II trials for monkeypox in Central Africa. In its quarterly report for the quarter ended September 30, 2025, the clinical-stage biotech company said NV-387 is engineered to resist viral escape.
NanoViricides closes $6M offering to fund operations
NanoViricides (NYSE-A:NNVC) said on Thursday it had closed a $6 million registered direct offering with a single healthcare institutional investor to support working capital and general corporate purposes. The Connecticut-based biotechnology company sold about 3.57 million shares of common stock, or equivalents, at $1.68 per share.
NanoViricides raises $6M in direct offering with institutional investor
NanoViricides (NYSE-A:NNVC) said on Tuesday it has entered into a securities purchase agreement with a single healthcare institutional investor to raise about $6 million through a registered direct offering. The company will sell 3.57 million shares of common stock, or equivalents, at $1.68 per share.
NanoViricides receives approval to start Phase II clinical trial of NV-387 for MPox treatment in DRC
NanoViricides (NYSE-A:NNVC) announced that it has received approval to begin its Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo (DRC). The clinical stage biotechnology company said the proposed Phase II clinical trial to evaluate safety and effectiveness of NV-387 for the treatment of patients with MPox disease caused by hMPXV infection is now cleared to proceed subject to filing of certain documents.
NanoViricides targets broad-spectrum virus threats – ICYMI
NanoViricides (NYSE-A:NNVC) CEO Dr Anil Diwan talked with Proactive about the company's latest progress with its broad-spectrum antiviral candidate, NV-387. Dr Diwan confirmed that NV-387 demonstrated strong results in a range of preclinical models, including measles, RSV, influenza, and Covid.
NanoViricides reports antiviral activity of NV-387 against measles in preclinical studies
NanoViricides (NYSE-A:NNVC) said on Wednesday its experimental drug NV-387 showed strong activity against the measles virus in both cell culture studies and a humanized animal model. The company said NV-387 treatment led to a 130% increase in survival time to 17 days from 7.4 days in mice infected with a lethal strain of the measles virus.
NanoViricides says lead drug NV-387 shows strong activity against Measles virus
NanoViricides (NYSE-A:NNVC) said on Monday its experimental antiviral drug NV-387 showed strong activity against the Measles virus in a humanized animal model, adding that it could be made available for emergency use as outbreaks spread across the US. The Connecticut-based company said NV-387 increased survival in Measles-infected animals by 130% compared with untreated ones, with no observed signs of toxicity.
NanoViricides says antiviral NV-387 may reduce cancer resurgence risk tied to viral infections
NanoViricides (NYSE-A:NNVC) said on Monday that its experimental broad-spectrum antiviral drug NV-387, now advancing into Phase II clinical trials, may help lower the risk of metastatic cancer returning in patients following viral infections. The company said recent studies have found that inflammation, particularly elevated levels of the cytokine IL-6 caused by infections such as COVID-19 and influenza, can reactivate dormant cancer cells, leading to the resurgence of metastatic disease.
NanoViricides says antiviral candidate NV-387 could address global measles surge
NanoViricides (NYSE-A:NNVC) said on Wednesday that its antiviral candidate NV-387 could play a key role in addressing the growing number of measles cases globally, particularly in industrialized nations including the US, Canada, the UK, and the EU. The company said NV-387 has shown safety and effectiveness in preclinical studies using humanized mouse models and has completed a Phase I clinical trial with no reported adverse events, supporting its potential as a measles treatment.
